urpose: To examine the prognosis of patients with intermittent claudication who received treatment with endovascular techniques. Methods: A retrospective multicenter study was performed involving 2930 consecutive patients (2307 men; mean age 71.568.9 years) with intermittent claudication who underwent an endovascular procedure for a de novo iliofemoral artery lesion. The primary outcome measure was overall survival. The secondary outcomes were freedom from major adverse cardiovascular events (MACE: all-cause death, myocardial infarction, and stroke) and from major adverse cardiovascular and limb events (MACE with repeat revascularization or above-knee amputation of the target limb). Cox multivariate regression analysis of selected baseline characteristics, procedure-related complications, and medication use was performed to determine predictors for all-cause mortality. Positive predictors from this analysis were used to stratify patients into low-(1410, 48.1%), moderate-(1406, 48.0%), and high-risk (114, 3.9%) categories. Results: The overall survival rates were 97.2%, 90.8%, and 83.4% at 1, 3, and 5 years, respectively. The cause of death was cardiovascular in 42.8% of cases. Freedom from MACE was 96.7%, 88.6%, and 77.3% at 1, 3, and 5 years, respectively. Cox multivariate regression analysis identified age, dialysis, left ventricular dysfunction, insulin-dependent diabetes, hematoma prolonging hospitalization, coronary artery disease, and superficial femoral plus iliac lesions as positive predictors of all-cause mortality. In the risk stratification analysis, the overall 5-year survival rate was significantly lower in high-risk patients compared to the other groups (90.1% vs. 78.6% vs. 53.5%, p,0.0001). Conclusion: The prognosis in patients with intermittent claudication after endovascular therapy was relatively good but extremely poor for the high-risk patient subgroup.
Atherosclerotic disease is increasing worldwide due to an aging population and changes in lifestyle. The increase in prevalence of peripheral artery disease (PAD) with increasing age is particularly significant. 1 The incidence of cardiovascular events is high in patients with PAD, 2 and outcomes in these patients differ between those with intermittent claudication (IC) and critical limb ischemia (CLI). The 1-year mortality is 25% in the natural course of CLI patients, whereas the 5-year mortality is 15% in patients with IC. 2 Therefore, some claudicant patients seem to have a relatively good prognosis compared to the patients with CLI. However, several largescale studies have found that the mortality rate of claudicant patients is 2.5 times higher than that of non-claudicant patients and that the risk of a fatal cardiovascular event is 3 to 6 times higher than that of non-claudicant patients. 1, 3, 4 See commentary page 389
In claudicant patients with limited exercise performance and walking capacity, revascularization procedures are the most effective way to improve symptoms. Both open repair/bypass surgery and endovascular therapy (EVT) can be used, and the TransAtlantic Inter-Society Consensus II (TASC II) guidelines recommend the choice of revascularization. Some recent reports have found that the patency rate of EVT is similar to that of surgery, 5, 6 but little is known about the long-term prognosis of claudicant patients after EVT. Therefore, in the present study, we evaluated the long-term prognosis for limb and life in claudicant patients with iliofemoral artery disease who underwent EVT.
METHODS

Study Design
Between January 2005 and December 2009, 7177 consecutive patients underwent EVT for iliofemoral artery disease [iliac artery and superficial femoral artery (SFA), excluding those with common femoral artery disease] at 18 Japanese institutions that participated in the study ( Fig. 1 ). Of these patients, 4045 were excluded because of a history of lower extremity bypass surgery or EVT (n¼333), restenotic lesions (n¼1612), CLI (n¼1499), Rutherford class ,2 (n¼312), acute onset limb ischemia (n¼162), persistent sciatic artery (n¼2), popliteal artery entrapment syndrome (n¼1), post amputation (n¼1), Angio-Sealrelated occlusion (n¼1), and inadequate data (n¼120).
Of the remaining 3132 cases, 2930 patients (2307 men; mean age 71.568.9 years, range 37-98) with IC affecting 3802 limbs were identified and retrospectively analyzed with regard to the primary and secondary outcomes after successful initial EVT for de novo iliofemoral occlusive lesions. Baseline clinical characteristics and procedure data were collected from hospital medical records or databases. Follow-up data were obtained from hospital charts or by contacting patients, family members, or referring physicians. The research protocol was approved by the ethics committee or relevant review board in all 18 participating centers, and the study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from every patient. 
Patient Sample
The characteristics of the patients and lesions are shown in Tables 1 and 2 . The 3802 lesions included 1352 in the iliac artery alone, 1616 in the SFA alone, and 834 in both arterial segments. According to the TASC II classification, 1560 (41.0%), 1037 (27.3%), 468 (12.3%), and 739 (19.4%) lesions were in classes A, B, C, and D, respectively. The mean follow-up period was 31.9620.9 months.
Outcome Measures and Definitions
The primary outcome was overall survival. Secondary outcomes were freedom from major adverse cardiovascular events [MACE: all-cause death, myocardial infarction (MI), and stroke] and freedom from major adverse cardiovascular and limb events (MACLE: MACE with any repeat target limb revascularization or above-knee amputation of the target limb).
Successful EVT was defined as ,30% residual stenosis without any procedural complication, which were defined as all-cause mortality, stroke, MI, intestinal bleeding, blood transfusion, prolonged hospitalization due to hematoma, pseudoaneurysm at the access site, distal embolization, worsened renal function, surgical repair, perforation or rupture, aortic dissection, stent thrombosis, or any other event prolonging hospitalization. MI was defined as creatine kinase (CK) or CK-MB above the upper limit of normal at each hospital or as development of significant Q waves in at least two contiguous leads of anT electrocardiogram. Stroke was defined as an ischemic event that persisted for 24 hours and was diagnosed by a neurologist.
Left ventricular dysfunction was based on an ejection fraction ,40%. Elderly age was defined as .70 years old. A calcified lesion referred to obvious densities noted within the vascular wall on the angiogram. Stent fracture was identified by radiography in .2 projections after restenosis, which was defined as a peak systolic velocity ratio .2.4 on duplex, .50% stenosis on angiography or computed tomography, or a 0.2 decrease of the resting ankle-brachial index.
Statistical Analysis
Continuous data are presented as the means 6 standard deviation; categorical data are given as the counts (percentage). Eventfree survival curves were estimated using the Kaplan-Meier method and compared by logrank test. Cox multivariate regression analysis of selected baseline characteristics, EVT complications, and medication use was performed to determine predictors for all-cause mortality; results are presented at the adjusted hazard ratio (HR) with the 95% confidence interval (CI). Clinically prespecified predictors [age, male gender, diabetes, hypertension, statin administration, current smoker, stroke, coronary artery disease (CAD), hemodialysis, TASC II C/D lesions, calcified lesion, complications as defined above, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEI/ARBs) administration, calcium antagonist administration, and stent fracture] achieving p,0.05 in the univariate analysis were entered into the multivariate Cox regression model. Risk stratification for all-cause mortality was performed using positive predictors identified in the multivariate analysis; factors with an adjusted HR 1.50 were scored as 2 points each and those with an HR ,1.50 as 1 point each. Scores of 0 to 2, 3 to 5, and 6 points stratified patients into the low-, moderate-, or high-risk subgroups, respectively. P,0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed with IBM SPSS Statistics software (version 21; IBM Corporation, Armonk, NY, USA).
RESULTS
The overall 1-, 3-, and 5-year survival estimates were 97.2%, 90.8%, and 83.4%, respectively ( Fig. 2) . Freedom from MACE was estimated at 96.7%, 88.6%, and 77.3% at the same time points, while freedom from MACLE estimates were 84.5%, 68.1%, and 58.7% (Fig.  2) . There was no significant difference in the overall 5-year survival estimates between patients with iliac and SFA lesions (91.3% vs. 92.1%, p¼0.54). Similarly, the 5-year freedom from MACE did not differ between the two types of lesions (88.2% vs. 88.8%, p¼0.33). However, there was a significant difference in the 5-year freedom from MACLE between iliac and SFA lesions (62.8% vs. 50.4%, p,0.0001). The overall 5-year survival was similar for Rutherford category 2/3 disease (83.9% vs. 83.2%, p¼0.11). The 5-year freedom from MACE was also similar in these two groups (89.3% vs. 88.1%, p¼0.27), but the 5-year freedom from MACLE was significantly higher in Rutherford class 2 cases (61.0% vs. 53.9%, p,0.0001). The overall 5-year survival was also similar for TASC II A/B and TASC II C/D lesions (81.6% vs. 87.3%, p¼0.27). The 5-year freedom from MACE was also similar between the patients with diabetes and those without (73.5% vs. 78.4%, p¼0.62); however, the 5-year freedom from MACLE was significantly lower in the patients with diabetes (49.9% vs. 62.0%, p,0.0001).
Mortality
There were 243 deaths during the follow-up period due to cardiac causes in 73 (30.0%) patients (18 owing to acute coronary syndrome, 16 to sudden death, and 19 to heart failure); vascular causes in 31 (12.8%) patients; and non-cardiovascular causes in 139 (57.2%) patients. Vascular death included stroke (10, 4.1%), ruptured aortic aneurysm (4, 1.6%), and renal failure (3, 1.2%). In total, cardiovascular death occurred in 104 (42.8%) patients.
Multivariate analysis performed using a Cox hazards model showed that elderly age, dialysis, left ventricular dysfunction, insulin administration, significant hematoma, CAD, and iliac þ SFA lesions were positive independent predictors of all-cause mortality ( Table 3 ). Administration of ACEI/ARB and of calcium antagonists were negative indepen-dent predictors of all-cause mortality. Stent fracture was not associated with mortality.
Risk stratification for all-cause mortality was based on the 7 positive predictors, with elderly age, dialysis, left ventricular dysfunction, insulin-dependent diabetes, and significant hematoma scored as 2 points each and CAD and iliac þ SFA lesions as 1 point each. Based on these scores, low-risk was assigned to 1410 (48.1%) patients, moderate-risk to 1406 (48.0%), and high-risk to 114 (3.9%) patients. The overall 5-year survival rate was significantly lower in high-risk patients than in the other 2 groups (90.1% vs. 78.6% vs. 53.5%, p,0.0001; Fig. 3A ). Freedom from MACE at 5 years was also significantly lower in high-risk patients (87.0% vs. 72.3% vs. 52.4%, p,0.0001; Fig. 3B ). Freedom from MACLE at 5 years was similarly significantly lower in high-risk patients (65.5% vs. 50.7% vs. 32.3%, p,0.0001).
Complications
The only complication of EVT found to be a predictor of all-cause mortality (HR 2.75, 95% CI 1.08 to 6.98, p¼0.034) was hematoma prolonging hospitalization, which occurred in 42 (1.4%) patients; 4 of these patients died within 60 days (all deaths were related to the hematoma). Four other patients died later due to acute coronary syndrome, abdominal aortic aneurysm (AAA) rupture, stroke, and malig-T 
DISCUSSION
Prior reports have consistently documented an increased overall 5-year mortality of~15% to 30% in patients with claudication. 2, 7 Our results show that the prognosis for survival of claudicant patients at 5 years after EVT was close to the natural course of PAD, suggesting that EVT does not worsen their prognosis. Patient mortality is significantly higher in the natural course of CLI than of IC. 2 The main cause of death of patients with PAD is cardiovascular; the Reduction of Atherothrombosis for Continued Health (REACH) registry found that about 3 in 5 patients with PAD had coronary artery or cerebrovascular disease. 8 Therefore, screening for polyvascular disease beyond the lower extremity artery should be performed during the diagnosis and management of PAD patients. Dormandy et al. 9 found that 40% to 60% of deaths involving PAD patients were associated with CAD, 10% to 20% with cerebrovascular disease, and 10% with other vascular diseases. The rates of cardiac, cerebrovascular, and other deaths in our study population were in line with these estimates, further supporting the recommendation that patients who undergo EVT should be screened for polyvascular disease.
Interestingly, we found no significant difference in all-cause mortality between patients with severe or mild claudication, in contrast to a previous report that the outcomes of CLI patients are poorer than those in claudicant patients. 1 Furthermore, we found no significant difference in all-cause mortality between claudicants with TASC II A/B and TASC II C/D lesions. However, patients at high risk for ischemic events were among the claudicant patients. Therefore, we assigned risk scores to classify patients with PAD, which proved useful for predicting all-cause mortality and ischemic events. The patients were evenly split between low-and moderate-risk, with ,4% categorized as high-risk cases.
The inclusion of EVT complications in the univariate analysis of possible factors influencing all-cause mortality returned some interesting findings. Significant hematoma prolonging hospitalization was responsible for 4 early deaths, and a further 4 patients died later (3 due to vascular events). While the other independent predictors of all-cause mortality are difficult to change, severe hematoma may be prevented by careful performance of EVT. The main cause of hematoma was an access site complication, which indicates that the puncture should be performed carefully and the access site should be checked frequently during the procedure. In our study, 7 of the 8 hematoma-related deaths involved a femoral artery access, which has a higher risk of complications in patients with advanced atherosclerosis. 10 Thus, additional care is needed when performing EVT from the femoral artery.
We also found that treatment with ACEI/ ARBs and with calcium antagonists had independent beneficial effects on prognosis. The efficacy of statins was also shown in univariate analysis. There is considerable evidence that ACEI/ARBs and statins are effective in primary and secondary prevention of cardiac disease, [11] [12] [13] [14] which suggests that these drugs may improve the prognosis of PAD patients. Calcium antagonists have been reported to have effects similar to those of ACEI/ARBs. 15 The general purpose of EVT is to extend the absolute claudication distance (ACD) and reduce leg pain during walking. Prior studies showed that successful revascularization of lower extremity arteries in claudicants improves functional status and quality of life. It is also associated with a reduction in major cardiovascular events 16, 17 due to extension of the ACD. 2, 6, 18 The increased walking ability after EVT is associated with improvements in blood pressure, lipid metabolism, and carbohydrate metabolism through exercise. 19, 20 EVT also improves endothelial dysfunction, 21 which plays a key role in the pathophysiology and natural history of atherosclerotic disease. 22 Patients with PAD typically have severe systemic atherosclerosis and poorer endothelial function compared to patients without PAD. 23 Among patients with PAD, poorer endothelial function is associated with higher rates of cardiovascular events. 24 A prior report also found that therapeutic exercise improves endothelial function. 25 Four points should be considered for improving the prognosis of patients after EVT: screening for polyvascular disease at the time of PAD diagnosis; avoidance of complications of EVT, especially severe hematoma; therapeutic exercise for patients after EVT; and intensive therapy for hypertension and dysli-pidemia using ACEI/ARBs, calcium antagonists, and statins.
This study has several limitations, including its retrospective nature and the absence of data on medication at the end of the follow-up period and on improving functional status and quality of life. Duplex ultrasound for detection of hematoma or pseudoaneurysm was not done routinely post intervention.
Conclusion
Within these limitations, we conclude that the prognosis after EVT is relatively good for most patients with claudication, but extremely poor for those patients at high risk for ischemic events.
